4tu8

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 8: Line 8:
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4tu8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tu8 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4tu8 RCSB], [http://www.ebi.ac.uk/pdbsum/4tu8 PDBsum]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4tu8 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4tu8 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4tu8 RCSB], [http://www.ebi.ac.uk/pdbsum/4tu8 PDBsum]</span></td></tr>
</table>
</table>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Purine interruptions of polypyrimidine (Py) tract splice site signals contribute to human genetic diseases. The essential splicing factor U2AF65 normally recognizes a Py tract consensus sequence preceding the major class of 3' splice sites. We found that neurofibromatosis- or retinitis pigmentosa-causing mutations in the 5' regions of Py tracts severely reduce U2AF65 affinity. Conversely, we identified a preferred binding site of U2AF65 for purine substitutions in the 3' regions of Py tracts. Based on a comparison of new U2AF65 structures bound to either A- or G-containing Py tracts with previously identified pyrimidine-containing structures, we expected to find that a D231V amino acid change in U2AF65 would specify U over other nucleotides. We found that the crystal structure of the U2AF65-D231V variant confirms favorable packing between the engineered valine and a target uracil base. The D231V amino acid change restores U2AF65 affinity for two mutated splice sites that cause human genetic diseases and successfully promotes splicing of a defective retinitis pigmentosa-causing transcript. We conclude that reduced U2AF65 binding is a molecular consequence of disease-relevant mutations, and that a structure-guided U2AF65 variant is capable of manipulating gene expression in eukaryotic cells.
 +
 +
Structure-guided U2AF65 variant improves recognition and splicing of a defective pre-mRNA.,Agrawal AA, McLaughlin KJ, Jenkins JL, Kielkopf CL Proc Natl Acad Sci U S A. 2014 Nov 24. pii: 201412743. PMID:25422459<ref>PMID:25422459</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
== References ==
 +
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>

Revision as of 12:04, 10 December 2014

STRUCTURE OF U2AF65 VARIANT WITH BRU5A6 DNA

4tu8, resolution 1.92Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools